Antifolate and antibacterial activities of 5-substituted 2,4-diaminoquinazolines.
A series of 5-substituted 2,4-diaminoquinazolines (3) has been synthesized and evaluated as inhibitors of the enzyme dihydrofolate reductase (DHFR) from both bacterial and mammalian sources. The best compounds (e.g. 53) show good activity against Escherichia coli DHFR, but there is no significant selectivity for the bacterial over the mammalian enzyme. The structure-activity relationships for enzyme inhibition appear to be complex and not amenable to simple analysis; a hypothesis to explain the observed qualitative structure-activity relationships is proposed. The inhibitory activities of the compounds against the growth of intact bacterial cells in vitro closely parallel those for the inhibition of the isolated bacterial enzymes, suggesting that their antifolate action is responsible for their antibacterial effects. Five of the compounds were tested for their ability to cure a systemic E. coli infection in the mouse, but they showed no therapeutic effects at their maximum tolerated doses.
Rhone-Poulenc Ltd., Dagenham Research Centre, Essex, England.
N V
NV
Harris
C
C
Smith
K
K
Bowden
D000818:Animals; D000900:Anti-Bacterial Agents; D002417:Cattle; D055598:Chemical Phenomena; D002621:Chemistry; D004926:Escherichia coli / Q000187:drug effects / Q000201:enzymology; D004927:Escherichia coli Infections / Q000188:drug therapy; D005493:Folic Acid Antagonists; D008099:Liver / Q000201:enzymology; D051379:Mice; D015394:Molecular Structure; D011799:Quinazolines / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use; D013211:Staphylococcus aureus / Q000187:drug effects; D013329:Structure-Activity Relationship
D000900:Anti-Bacterial Agents; D005493:Folic Acid Antagonists; D011799:Quinazolines; C013474:2,4-diaminoquinazoline